Royalty Pharma
(NASDAQ:RPRX)
$28.05
0.08[0.29%]
At close: May 10
$28.05
0[0.00%]
PreMarket: 7:00AM EDT
The dividend Ex-Date is in 6 days
Q1 2024 Earnings were released on Thu May 9th, before the market open
The most recent conference call was at 8:00 AM, 1 day ago Click to view past webcast
ImmuNext, Inc announced it will sell assets to Royalty Pharma (RPRX) on Thursday, May 9, 2024 for $525.0M paid in cash
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
62.5%
Overview Rating
Good
Technicals Analysis
66
0100
Financials Analysis
60
0100

Royalty Pharma Stock (NASDAQ:RPRX), Quotes and News Summary

Royalty Pharma Stock (NASDAQ: RPRX) stock price, news, charts, stock research, profile.

Open-
Close-
Volume / Avg.649.000 / 2.865M
Day Range- - -
52 Wk Range25.920 - 35.520
Market Cap$12.650B
P/E Ratio15.713
Dividend Yield3.000%
ExchangeNASDAQ
RSI
55
Short Interest
3.26%
Days to Cover5.4

Recent News

Royalty Pharma Beats Q1 Earnings and Revenue Estimates
Royalty Pharma (NASDAQ: RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago. These figures are adjusted for non-recurring items.
Zacks
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.
Erica Kollmann
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Wednesday, there were a few notable insider trades.
Lisa Levin
60%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
2
Feb
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
RPRX
NVO

FAQ

Q

How do I buy Royalty Pharma (RPRX) stock?

A

You can purchase shares of Royalty Pharma (NASDAQ: RPRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Royalty Pharma's (RPRX) competitors?

A

Other companies in Royalty Pharma’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).

Q

What is the target price for Royalty Pharma (RPRX) stock?

A

The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by B of A Securities on Friday, April 12, 2024. The analyst firm set a price target for 38.00 expecting RPRX to rise to within 12 months (a possible 35.47% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Royalty Pharma (RPRX)?

A

The stock price for Royalty Pharma (NASDAQ: RPRX) is $28.05 last updated Today at May 10, 2024 at 7:00 AM EDT.

Q

Does Royalty Pharma (RPRX) pay a dividend?

A

The next Royalty Pharma (RPRX) dividend date is projected to be Thursday, May 16, 2024.

Q

When is Royalty Pharma (NASDAQ:RPRX) reporting earnings?

A

Royalty Pharma’s Q2 earnings are confirmed for Tuesday, August 6, 2024.

Q

Is Royalty Pharma (RPRX) going to split?

A

There is no upcoming split for Royalty Pharma.

Q

What sector and industry does Royalty Pharma (RPRX) operate in?

A

Royalty Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch